The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System. Eligible participants have stage 4 metastatic solid tumor(s), that is(are) not responding to conventional treatment or have declined standard treatment options. The main question it aims to answer is: • What is the safety profile of the Sarah Nanotechnology System and which field strength and time of irradiation are safe for people? Study participation involves: * One intravenous injection (through a vein in the arm) of a solution that contains tiny particles (nanoparticles) containing iron oxide. The nanoparticles are delivered to the tumor(s) through blood circulation. * About 4 hours after injection of the nanoparticles, participants are placed inside a machine (magnetic field system) where the upper torso will be exposed to low frequency (\~300 kHz) alternating magnetic field (AMF) radiation. This type of radiation, unlike CT or X- rays, is non-ionizing. Non-ionizing means radiation that lacks the energy to remove electrons from an atom. Examples of devices that produce non-ionizing radiation are MRI machines, cell phones, Wi-Fi, microwave ovens, and sunlight. The AMF heats up the iron oxide core in the nanoparticles, due to their magnetic properties, which in turn causes the temperature to increase within the tumor(s). Because cancer cells are more sensitive to heat than normal cells, the heat will damage the cancer cells potentially without harming the surrounding healthy tissues. * During the treatment participants are covered by a cooling blanket to control body temperature, which will be monitored continuously throughout the procedure. * Participants are followed up at 1 week and 1 month, and up to 5 years after the one-time treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Spodziewana długość życia co najmniej 90 dni.
- •Potwierdzony nowotwór rozwinięty z przerzutami w obszarze od klatki piersiowej do miednicy, który nie reaguje na standardowe leczenie i nie można go operować.
- •Chorobę można zmierzyć obrazowo (widoczne zmiany na tomografii).
- •Wiek co najmniej 18 lat.
- •Obwód klatki piersiowej nie więcej niż 90 cm.
- •Ogólny stan zdrowia oceniony na 0-2 w skali ECOG (pacjent potrafi się opiekować sobą).
- •Właściwe wyniki krwi: białe krwinki, płytki, wątroba, nerki w normie.
- •Brak metalowych implantów w ciele (potwierdzonym przeglądem tomografii i ankietą).
✗ Disqualifies
- •Chemioterapia, radioterapia lub hormonoterapia w ciągu ostatnich 14 dni.
- •Immunoterapia lub inne badane leki w ciągu ostatnich 21 dni.
- •Skutki uboczne z poprzedniego leczenia raka nie całkowicie ustąpiły.
- •Przerzuty do mózgu lub historia przerzutów do mózgu.
- •Alergia na podobne związki chemiczne.
- •Niekontrolowana choroba współistniejąca (infekcja, problemy z sercem, niestabilna choroba wieńcowa, zaburzenia psychiczne).
- •Ciąża lub karmienie piersią.
- •Metalowe lub elektroniczne implanty w ciele.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- May 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Mayo Clinic
Rochester, United States
Trial contact
New Phase Clinical Team
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.